百奥赛图业绩快报：2025年归母净利润1.73亿元，同比增长416.37%

Core Insights - The company reported a total operating revenue of 1.379 billion yuan for the fiscal year 2025, representing a year-on-year growth of 40.63% [1] - The net profit attributable to shareholders reached 173 million yuan, showing a significant year-on-year increase of 416.37% [1] - Basic earnings per share were reported at 0.43 yuan, indicating strong financial performance [1] Revenue Growth Drivers - The substantial growth in operating revenue is primarily attributed to the continuous expansion in overseas markets [1] - The recovery and rebound of the domestic biopharmaceutical industry also contributed to the company's impressive revenue growth [1]